TY  - GEN 
AU  - Moreno-Pérez, D.
AU  - Korobova, A.
AU  - Croche-Santander, F.D.B.
AU  - Cordón-Martínez, A.
AU  - Díaz-Morales, O.
AU  - Martínez-Campos, L.
AU  - Pérez-González, E.
AU  - Martínez-Padilla, M.D.C.
AU  - Santos-Pérez, J.L.
AU  - Brioso-Galiana, J.
AU  - Sánchez Codez, María Isabel
AU  - Del Diego-Salas, J.
AU  - Rivera-Izquierdo, M.
AU  - Lorusso, Nicola
A4  - Materno-Infantil y Radiología
PY  - 2025
SN  - 2076-393X
UR  - http://hdl.handle.net/10498/36317
AB  - Background: Nirsevimab was indicated in a population level for all infants < 6 months during the 2023–2024 season in Andalusia (southern Spain). Our aim was to analyse the effect of nirsevimab in the reduction in complications in infants hospitalised...
LA  - eng
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
KW  - clinical effectiveness;
KW  - disease severity
KW  - immunisation
KW  - monoclonal antibodies
KW  - paediatric
KW  - respiratory complications
KW  - tertiary prevention
TI  - Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023–2024 Season in Andalusia, Spain (NIRSEGRAND)
DO  - 10.3390/vaccines13020175
ER  -